NYSE:MET
38.32
0.43
(1.12%)
MetLife, Inc. is the holding corporation for the Metropolitan Life Insurance Company, better known as MetLife, and its affiliates.
More at Wikipedia
Metlife
MET-N
Analysis and Opinions about MET-N
Signal
Opinion
Expert
COMMENT
COMMENT
January 30, 2020
AIG-N vs. MET-N. AIG-N has been recapitalizing since the disaster of the financial crisis. MET-N did not suffer these issues. The life business is in pretty decent shape but he prefers Canadian lifecos. (Analysts’ price target is $55.57)
BUY
BUY
September 20, 2019
It’s pretty cheap, trading at 8.1 times. Their earnings in July were double year over year and beat expectations. They are growing globally and it’s a safe name with a low valuation. Couldn’t go wrong with this choice in the long term.
Show full opinionHide full opinionIt’s pretty cheap, trading at 8.1 times. Their earnings in July were double year over year and beat expectations. They are growing globally and it’s a safe name with a low valuation. Couldn’t go wrong with this choice in the long term.
WAIT
WAIT
August 8, 2019
MET vs. BAC. Dynamics of the two are different, so hard to compare. FMV potential of both is huge. But the market won't go, because interest rates are falling. Aren't any drivers to escalate earnings. Very cheap, but who knows when they're going to pop? (Analysts’ price target is $53.19)
Show full opinionHide full opinionMET vs. BAC. Dynamics of the two are different, so hard to compare. FMV potential of both is huge. But the market won't go, because interest rates are falling. Aren't any drivers to escalate earnings. Very cheap, but who knows when they're going to pop? (Analysts’ price target is $53.19)
DON'T BUY
DON'T BUY
June 14, 2019
The balance sheet is impaired and there should be write-offs, which he hasn't seen. He sees 32% upside with a $64 model price, but he'd be happy seeing this at $53.80. He would recommend this stock above this price. He has recommended MET before, but MET just can't get going. The balance sheet is ugly. Also, if interest rates fall to zero, all insurance companies will get hit.
Show full opinionHide full opinionThe balance sheet is impaired and there should be write-offs, which he hasn't seen. He sees 32% upside with a $64 model price, but he'd be happy seeing this at $53.80. He would recommend this stock above this price. He has recommended MET before, but MET just can't get going. The balance sheet is ugly. Also, if interest rates fall to zero, all insurance companies will get hit.
PAST TOP PICK
PAST TOP PICK
March 18, 2019
(A Top Pick Mar 29/18, Up 3%) Slow or flar growth this and next year, but they are buying back stock. He sees 9% EPS growth this year. Their US retirement portfolio has been doing well. It's cheap at 8x PE and paying almost a 4% dividend. It's been stagnant for many years, but it has tailwinds of lower taxes and volume growth. They're growing in Asia and Europe.
Show full opinionHide full opinion(A Top Pick Mar 29/18, Up 3%) Slow or flar growth this and next year, but they are buying back stock. He sees 9% EPS growth this year. Their US retirement portfolio has been doing well. It's cheap at 8x PE and paying almost a 4% dividend. It's been stagnant for many years, but it has tailwinds of lower taxes and volume growth. They're growing in Asia and Europe.
DON'T BUY
DON'T BUY
March 6, 2019
Metlife vs. Prudential vs US banks Both are high quality and international. Strong. He doesn't love lifecos now, because there's a lot going on in health, such as the prevalance of diabetes. He wants to see higher interest rates which can benefit lifecos. As for banks, he'd stay away. The rates and yield curve have flattened. Met are doing the right thing, like a nice dividend and a big share buybacks. It isn't expensive and doing 10% earnings growth, but there are greener pastures elsewhere.
Show full opinionHide full opinionMetlife vs. Prudential vs US banks Both are high quality and international. Strong. He doesn't love lifecos now, because there's a lot going on in health, such as the prevalance of diabetes. He wants to see higher interest rates which can benefit lifecos. As for banks, he'd stay away. The rates and yield curve have flattened. Met are doing the right thing, like a nice dividend and a big share buybacks. It isn't expensive and doing 10% earnings growth, but there are greener pastures elsewhere.
COMMENT
COMMENT
February 8, 2019
Insurance companies are trading below their lower benchmarks -- making him think there are issues with their balance sheets especially in a deflationary recession environment. This could lead to lower short term rates, which could impair their earnings. He would be cautious going forward for all insurance companies.
Show full opinionHide full opinionInsurance companies are trading below their lower benchmarks -- making him think there are issues with their balance sheets especially in a deflationary recession environment. This could lead to lower short term rates, which could impair their earnings. He would be cautious going forward for all insurance companies.
DON'T BUY
DON'T BUY
December 10, 2018
SLF-T vs. MET-N. He prefers Sunlife (SLF-T). It is higher quality and more defensive. Also they are down with the sector. There is more competition in the US vs. Canada.
Show full opinionHide full opinionSLF-T vs. MET-N. He prefers Sunlife (SLF-T). It is higher quality and more defensive. Also they are down with the sector. There is more competition in the US vs. Canada.
PAST TOP PICK
PAST TOP PICK
July 17, 2018
(A Top Pick July 11, 2017. Down 7%). This has gone down even as interest rates have come up. He is holding with it, with a very small position. Life insurers are not participating in the financials rally as much as he expected. His model price shows a 47% upside, but the market appears to dislike some aspect of MetLife’s balance sheet and he is not sure what that is. Because he is not sure what is wrong, he would not buy it.
(A Top Pick July 11, 2017. Down 7%). This has gone down even as interest rates have come up. He is holding with it, with a very small position. Life insurers are not participating in the financials rally as much as he expected. His model price shows a 47% upside, but the market appears to dislike some aspect of MetLife’s balance sheet and he is not sure what that is. Because he is not sure what is wrong, he would not buy it.
COMMENT
COMMENT
May 29, 2018
One of the biggest life insurance companies. Spawned off the individual insurance part in a company called Brighthouse earlier this year. MetLife has been hurt lately by some controversy. In the long run still likes the outlook for both Brighthouse and Metlife, and rising interests rate do help insurance companies a lot.
One of the biggest life insurance companies. Spawned off the individual insurance part in a company called Brighthouse earlier this year. MetLife has been hurt lately by some controversy. In the long run still likes the outlook for both Brighthouse and Metlife, and rising interests rate do help insurance companies a lot.
PAST TOP PICK
PAST TOP PICK
April 25, 2018
(A Top Pick July 11/17 Down 2%) All the insurers are being helped by rising interest rates, yet the stock price has not increased. He is disappointed by the performance, but will continue to stick with it. He has a model price about 30% higher. Yield 3.5%.
(A Top Pick July 11/17 Down 2%) All the insurers are being helped by rising interest rates, yet the stock price has not increased. He is disappointed by the performance, but will continue to stick with it. He has a model price about 30% higher. Yield 3.5%.
PAST TOP PICK
PAST TOP PICK
April 19, 2018
(A Top Pick May 1/17, Up 5%) It spun out Bright House. He continues to own both. They had to take a hit on benefits that people were not getting and should have.
(A Top Pick May 1/17, Up 5%) It spun out Bright House. He continues to own both. They had to take a hit on benefits that people were not getting and should have.
DON'T BUY
DON'T BUY
April 11, 2018
This is a diversified insurance company with a bias to life. It is in a good capital situation. The technical chart is too boom and bust, which he can’t explain. Insurance broadly has generally under-performed and he thinks you are taking more risk than the reward you are getting. He would prefer straight financial stocks instead.
This is a diversified insurance company with a bias to life. It is in a good capital situation. The technical chart is too boom and bust, which he can’t explain. Insurance broadly has generally under-performed and he thinks you are taking more risk than the reward you are getting. He would prefer straight financial stocks instead.
TOP PICK
TOP PICK
March 29, 2018
A sleepy little story. It is really cheap. He likes it for strong buybacks, dividend growth and upping their return on equity. 11% forecast earnings growth. (Analysts’ target: $55.00).
A sleepy little story. It is really cheap. He likes it for strong buybacks, dividend growth and upping their return on equity. 11% forecast earnings growth. (Analysts’ target: $55.00).
PAST TOP PICK
PAST TOP PICK
January 25, 2018
(A Top Pick Jan 13/17. Up 15%.) Still likes this. It’s trading at about 1X Price to Book, which is cheap in the financial world. Pays about a 3% dividend, which is expected to grow 6%-7% over the next several years. Right now, the 10-year treasury is above 260 and rising interest rates will help companies like this. They have very strong international operations. 3% dividend yield.
(A Top Pick Jan 13/17. Up 15%.) Still likes this. It’s trading at about 1X Price to Book, which is cheap in the financial world. Pays about a 3% dividend, which is expected to grow 6%-7% over the next several years. Right now, the 10-year treasury is above 260 and rising interest rates will help companies like this. They have very strong international operations. 3% dividend yield.
Metlife(MET-N) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Metlife(MET-N) Frequently Asked Questions
What is Metlife stock symbol?
Metlife is a American stock, trading under the symbol MET-N on the New York Stock Exchange (MET). It is usually referred to as NYSE:MET or MET-N
Is Metlife a buy or a sell?
In the last year, 1 stock analyst published opinions about MET-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Metlife.
Is Metlife a good investment or a top pick?
Metlife was recommended as a Top Pick by Lorne Steinberg on 2020-01-30. Read the latest stock experts ratings for Metlife.
Why is Metlife stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Metlife worth watching?
1 stock analyst on Stockchase covered Metlife In the last year. It is a trending stock that is worth watching.
What is Metlife stock price?
On 2020-07-15, Metlife (MET-N) stock closed at a price of $38.315.
